Accumulating evidence supports the existence of nonthyroidal calcitonin (CT)-like peptides, more similar to fish CTs, which may act as endogenous regulators of CT receptors in brain and other tissues. In this study, we have carried out large-scale extractions from SpragueDawley rat brain diencephalon and pituitary, and purified a novel, biologically active, CT-like peptide from pituitary. Monitoring of the calcitonin-like activity of the peptides from rat brain and pituitary required different detection systems. While the brain CT cross-reacted with C-terminally directed salmon CT-specific antisera, the pituitary CT did not. However, the pituitary CT was biologically active, exhibiting specific interaction with CT receptors to activate adenylate cyclase. Conventional chromatographic techniques were employed to purify the CT-like peptides. Although the brain CT was not purified to homogeneity, size exclusion chromatography revealed the presence of multiple molecular weight forms of immunoreactive CT. Of these, only the lowest molecular weight form was biologically active. Purification from the pituitary resulted in the isolation of a biologically active peptide with a mass of 3267 Da. This mass differs from the mass of both salmon and thyroid-derived rat CT. Initial amino acid sequencing of the pituitary CT indicated that it was Nterminally blocked. Following aminopeptidase digestion, a unique six amino acid sequence, EKSQSP, was identified. Elucidation of the amino acid composition provided supporting evidence that the peptide was novel and was consistent with a full length peptide of approximately 30 amino acids. These data support the existence of novel, nonthyroidal, CTs which are potential regulators of CT receptormediated functions. (Endocrinology 139: [982][983][984][985][986][987][988][989][990][991][992] 1998) 
T HE CENTRAL nervous system (CNS) of a variety of species contain abundant calcitonin (CT) receptors, which are responsive to exogenous CT. However, the endogenous ligand that interacts with these receptors is unknown. CT is believed not to cross the blood brain barrier to any significant extent (1), although very low concentrations of the thyroid-derived form of CT have been detected in both hypothalamus and pituitary of humans and rats (2) (3) (4) . CT messenger RNA expression is low or undetectable in brain and pituitary (5) (6) (7) .
In addition to human CT-like immunoreactivity (hCT-I), salmon CT-like immunoreactivity (sCT-I) occurs in human brain extracts (8) . Similarly, a biologically active sCT-like peptide is present in extracts of rat diencephalon (9) . A role for a sCT-like peptide as a neurotransmitter/neuromodulator is supported by the presence of sCT-I within the CNS of lower vertebrates. In pigeon (10) , the levels and distribution of sCT-I are consistent with our findings in rat brain (9) , with the highest amount detected in the hypothalamus, followed by the midbrain, and low levels in brain stem. Immunohistochemical studies in lizard brain localized sCT-I to varicosities and terminals in the diencephalon, although not in other brain regions (11) . Furthermore, the rat C1b CT receptor isoform has very little interaction with the thyroid-derived form of CT (12, 13) . This receptor isoform is abundant in rat brain, exhibiting an almost parallel distribution to the C1a receptor (14) . For this receptor to be physiologically meaningful, a CT-like ligand, distinct from the thyroid-derived form (such as the sCT-I molecule) must exist in rat brain.
Salmon CT-I is also released from cultured rat anterior pituitary cells (15) , and intense sCT-I staining occurs in the mouse pituitary carcinoma cell line, ␣-TSH (16) . Although the physiological significance of CT-like material in the pituitary remains to be fully determined, CT receptors occur in the intermediate pituitary (14, 17) and in ␣-TSH cells (18) , suggesting a possible paracrine role. Accordingly, Shah et al. (15) demonstrated that anti-sCT serum stimulates PRL release in cultured anterior pituitary cells, suggesting that the sCT-like peptide in the anterior pituitary gland exerts an inhibitory paracrine influence on PRL secretion.
The existence of multiple types of CT within one species is supported by the immunological detection of at least two forms of CT in fish, reptiles, amphibia, mammals and birds (19, 20) . The existence of a gene expressing a sCT-like peptide in humans is also supported by hybridization of chicken CT cDNA to Northern blots of human medullary thyroid carcinoma tissue (21) . This paper describes the purification and partial characterization of CT-like activity from rat pituitary and diencephalon. 20) , hCT(1-16)/sCT(17-32) (ACT 15), hCT(1-21)/sCT (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (ACT 19) and sCT(1-16)/hCT(17-32) (ACT 27) were a gift from Dr. Eigoro Murayama (Chugai Pharmaceutical Co., Shizuoka, Japan). BSA was obtained from Commonwealth Serum Laboratories (CSL; Parkville, Victoria, Australia). The cAMP antibody was a gift from Dr. Phil Marley (Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia). Bacitracin, isobutylmethylxanthine, and theophylline were from Sigma Chemical Co. (St. Louis, MO). Na 125 I was from Amersham (Buckinghamshire, UK). Tissue culture flasks were from Nunc (Roskilde, Denmark), and 12-and 24-well plates were from Becton Dickinson Labware (Lincoln Park, NJ). DMEM, N-2-hydroxyethylpiparazine-NЈ-2-ethanesulfonic acid (HEPES), and geneticin (neomycin antibiotic G418 sulfate) were from GIBCO-BRL Life Technologies, Inc. (Grand Island, NY). Standard antibiotics used in the media; gentamicin and minocycline were from David Bull Laboratories (Mulgrave, Victoria, Australia) and Sigma, respectively. FBS was from Cytosystems Pty. Ltd. (Castle Hill, New South Wales, Australia) and trypsin from CSL. The Vydac C18 resin (20 -30 m) was purchased from The Separations Group (Hesperia, CA). The SP Sepharose HP (16/10) column and Sephadex G-50 (Superfine) resin were from Pharmacia (Amrad Pharmacia Biotech, New South Wales, Australia). Brownlee reverse-phase 300 C8 columns were from Applied Biosystems, Inc. (Foster City, CA) and Hypersil C18 reverse-phase columns were purchased from Phenomenex (Torrance, CA). The microbore SGE column was from SGE (Ringwood, Victoria, Australia). Bradford protein assay dye was from Bio-Rad Laboratories (Hercules, CA). Sep-Pak C18 cartridges (360 mg silica) were purchased from Millipore Corporation (Milford, MA). Acetonitrile (HPLC grade) was purchased from Mallinkrodt Speciality Chemicals Co. (Paris, KN). Trifluoroacetic acid (TFA) was from Auspep (Parkville, Victoria, Australia). Tween-20 detergent, heptafluorobutyric acid (HFBA), and triethylamine (TEA) were from Pierce (Rockford, IL). Nonsterile, nylon 0.45-m filters were from Activon Scientific Product Co. Pty. Ltd. (Pennant Hills, New South Wales, Australia). Phenylmethylsulfonyl-fluoride, pepstatin, benzamidine, leupeptin, aprotinin, and ribonuclease A were purchased from Sigma. Blue Dextran 2000 was obtained from Pharmacia. Sequencing grade Asp-N aminopeptidase and pyroglutamate aminopeptidase were from Boehringer Mannheim (Mannheim, Germany). Endoprotease Lys-C was purchased from Wako (Tokyo, Japan) and modified, sequencing grade trypsin from Promega (Madison, WI). All other chemicals were of analytical grade unless otherwise stated.
Materials and Methods Materials

Cell culture
Human embryonic kidney (HEK)-293 cells and HEK-293 cells stably transfected with either the rat C1a or rat C1b CT receptor were maintained in DMEM containing 5% FBS, 80 mg/liter gentamicin, 1 mg/liter minocycline, and 15 mm HEPES, at 37 C in a humidified atmosphere of 5% carbon dioxide in air. The stable C1a CT receptor expressing (D11; ϳ600,000 receptors/cell; passage 50 -60) and C1b CT receptor expressing (B8-H10; ϳ6,000,000 receptors/cell; passage ϳ90) cell lines were generated as previously described (13) with selection pressure maintained with 200 g/ml geneticin.
sCT RIA
Synthetic sCT was iodinated using a modified chloramine-T method as previously described (22) and purified by reverse-phase high pressure liquid chromatography (HPLC) to a specific activity of 2000 Ci/mmol. The anti-sCT antisera (1464) was raised in rabbits using a synthetic sCT analog R 11,18 K 14 sCT (23) conjugated to BSA as antigen. It was used in the RIA, described below, at a final titer of 1:30,000, with a detection limit of ϳ10 pg/tube. The antibody is 100% cross-reactive to sCT and less than 0.1% cross-reactive to hCT or rat CT (rCT). During the course of this work, Hanna et al. (16) demonstrated, immunohistochemically, presence of sCT-I in mouse ␣-TSH cells (derived from a pituitary carcinoma), using a commercial anti-sCT antibody (Peninsula, Belmont, CA). As a consequence, this antibody (designated PAb) was also used for RIA. PAb was used at a final titer of 1:24,000, with a detection limit of approximately 3 pg/tube. The antibody is reported by the supplier to be 100% cross-reactive with sCT, eel CT, and chicken CT but does not cross-react with hCT, rCT, PDN-21, human and rat amylin, or human CT generelated peptide. Subsequent analysis of antibody specificity using chimeric sCT/hCT peptides (ACT15, ACT19, ACT20, ACT27) indicated that both antisera were C-terminally directed, with the primary epitope located between residues 22 and 32 (not shown). Before assay, salt or detergent was removed from samples by application to C18 Sep-Pak cartridges, and elution using 3 ml 80% acetonitrile/0.1% TFA. The eluates were frozen on dry ice, lyophilized, and stored at Ϫ20 C until assayed.
For RIA, lyophilized samples were reconstituted in RIA buffer (0.1 m sodium phosphate, pH 7.2, containing 0.1% BSA and 0.02% (wt/vol) sodium azide) and were assayed in duplicate. A standard curve for sCT was constructed using 10 -100,000 pg sCT. Nonspecific binding tubes contained excess (100 ng) sCT. Tubes containing sample or sCT standard were vortexed and incubated for approximately 16 h at 4 C.
125 I-sCT (10,000 Ϯ 2,000 cpm) was then added, the tubes vortexed, and incubated at 4 C overnight. Separation of bound ligand from free was achieved by the addition of 0.5 ml bovine ␥-globulin (3.0 mg/ml; Sigma) and 1.5 ml of 20% polyethylene glycol (average molecular weight 8000; Sigma). The tubes were vortexed, and incubated at 4 C for 15 min, before centrifugation for 15 min at 5,000 ϫ g in a Beckman J-6 M/E centrifuge (Palo Alto, CA) at 4 C. Supernatants were aspirated and the pellets counted on a Packard ␥-counter (70% efficiency; Packard, Downers Grove, IL).
cAMP assay
Cells in 24-well plates were preincubated for 20 min, at 37 C, in a humidified incubator with 5% CO 2 , in growth medium containing 0.1% (wt/vol) BSA and 1 mm isobutylmethylxanthine (this step was omitted for C1b receptor expressing cells due to their high basal levels of cAMP; 13). Cells were subsequently incubated for 20 min either with increasing concentrations of sCT (sCT standard curve) or with lyophilized samples from chromatography runs that had been reconstituted in the incubation media. Samples were assayed in duplicate. Following incubation, cells were washed with PBS (140 mm NaCl, 2 mm KCl, 1 mm KH 2 PO 4 , 8 mm Na 2 HPO 4 ) and the cAMP extracted with 0.5 ml of absolute ethanol. Levels of cAMP were assayed using a specific RIA as previously described (24) .
Peptide purification
For small-scale studies, Sprague-Dawley rats (200 -250 g) were killed by decapitation and rat pituitaries and rat brain diencephalon (principally hypothalamus) were rapidly removed and frozen by immersion into isopentane cooled with dry ice. For large-scale purification, 3000 fresh frozen rat pituitaries and 4000 rat diencephalons were obtained from Harlan Bioscience Products (Indianapolis, IN). Tissues were stored at Ϫ70 C until processing. The procedures used for peptide purification are similar to those developed by Bennett, Browne and Solomon for the purification of pituitary peptides (25, 26) .
A number of different extraction media and conditions were examined before selecting a protocol of tissue-homogenisation, at 4 C, in an acid mix media comprising 1 m HCl, containing 5% formic acid, 1% TFA, 1% NaCl, 1 mm phenylmethylsulfonyl-fluoride, 10 g/ml pepstatin, 1 mm EDTA, 10 mm benzamidine and 20 g/ml leupeptin, as the most efficient. Following homogenization, crude extracts were centrifuged at 30,000 ϫ g for 30 min at 4 C, the supernatant filtered through Miracloth and then lyophilized. This protocol was used for all tissue extractions in this study. Protein levels were monitored by Bradford protein microassay (27) using bovine ␥-globulin as the standard. For efficient extraction in large-scale purification, tissue was divided into batches of 500 diencephalon/250 ml or 1000 pituitaries/100 ml of acid mix media and homogenized for approximately 1 min, at 4 C. Following centrifugation, supernatants were pooled and filtered through Miracloth. The supernatant was again divided into aliquots of 250 ml for diencephalon or 100 ml for pituitary, placed in glass 1 liter roundbottom flasks, frozen, and lyophilized.
Preparative chromatography
Vydac C18 chromatography. Vydac C18 resin was swollen in 20% acetonitrile/0.1% TFA and packed into a HR column (16/5) (Pharmacia). This column was used as an initial step in protein purification to desalt the tissue extract. The Vydac C18 column was connected to a fast protein liquid chromatography (FPLC) system (Pharmacia). Lyophilized sample was reconstituted in buffer A (10% acetonitrile/0.1% TFA), passed through a 0.45-m filter, and loaded onto the column at a flow rate of 1 ml/min. The column was washed with at least 30 ml buffer A at a flow rate of 2 ml/min. Batch elution was achieved with 10 -20 ml buffer B (90% acetonitrile/0.1% TFA), and eluates were frozen and lyophilized.
Preparative cation exchange (CEX) chromatography was performed using a SP Sepharose HP (16/10) column connected to the FPLC system. Batch elution of tissue extract was performed. The CEX chromatography was performed at pH 5. For large-scale purification, lyophilized sample was reconstituted in buffer A (20 mm ammonium acetate, 40% acetonitrile, 0.1% TFA, 0.02% (vol/vol) Tween-20), passed through a 0.45-m filter, and loaded onto the column at a flow rate of 1 ml/min. The column was preequilibrated and washed with 60-ml buffer A at a flow rate of 2 ml/min. Sample was batch eluted with at least 30 ml buffer B (buffer A ϩ 1 m guanidinium hydrochloride [GuHCl], pH 5.0) and collected into TFA at a final concentration of 0.5%, to reduce the pH and thus prevent degradation. The eluate was frozen and lyophilized.
Sephadex G-50 size exclusion chromatography
To prevent noncovalent aggregation between CT-like peptides or with other proteins, size exclusion chromatography (SEC) was performed under denaturing conditions, in 6 m GuHCl. Sephadex G-50 resin was swollen in 6 m GuHCl, pH 3, for at least 3 h at room temperature (ϳ22 C). The resin was degassed for 30 min and a glass column (100 ϫ 1.5 cm; Pharmacia) packed, and allowed to settle for 1-2 days at room temperature. Blue Dextran 2000 (2 mg/ml) was applied to the column to determine the void volume and to check the homogeneity of the column bed before sample application. Lyophilized sample was reconstituted in the SEC buffer (6 m GuHCl, pH 3) and glycerol added to a final concentration of 10% (vol/vol). The sample was passed through a 0.45-m filter before application. For brain extract, an additional step of immersion into a boiling water bath for 10 min and rapid cooling on ice was also included before loading onto the column. The column was run under gravity. Fractions were collected every 30 min into polypropylene tubes.
Preparative C8 reverse-phase HPLC
A Brownlee C8 reverse-phase column (100 ϫ 10 mm) was connected to a Waters 600 series HPLC (Waters, Milford, MA). Samples were reconstituted in buffer A (20% acetonitrile/0.1% TFA), unless otherwise stated, passed through a 0.45-m filter, and loaded onto the column at a flow rate of 1 ml/min. Elution was achieved using a linear gradient of 20 -60% acetronitrile/0.1% TFA at a flow rate of 3 ml/min over a period of 60 min. Fractions were collected every minute and lyophilized before assay.
Analytical C8 reverse-phase HPLC
A Brownlee C8 reverse-phase column (250 ϫ 4.6 mm) was connected to the Waters HPLC system. Sample was reconstituted in buffer A (10% acetonitrile/0.1% TFA), passed through a 0.45-m filter, and loaded onto the column. The flow rate was 1 ml/min. Elution was achieved with a linear gradient of 20 -50% acetonitrile/0.1% TFA over 60 min.
Narrowbore reverse-phase HPLC
Narrowbore columns were connected to a HP1090 series II liquid chromatograph (Hewlett Packard Company, Waldbronn, Germany). Unless otherwise stated, the narrowbore reverse-phase HPLC was performed as follows. Sample was loaded onto the column at a flow rate of 250 l/min, and elution was achieved using a linear gradient of 0 -60% acetonitrile/0.1% TFA at a flow rate of 100 l/min. Fractions were collected manually into 1.5 ml polypropylene tubes, frozen and stored at Ϫ70 C.
Aminopeptidase digestions
Aliquots of peptide were diluted 1:5 with the appropriate buffer (see below) before addition of enzyme. Trypsin (1.0 g) digests were performed for 18 h, at 37 C, in 0.1 m Tris-HCl, pH 8, containing 10% (vol/vol) acetonitrile. Asp-N (0.2 g) digests were performed for 18 h, at 37 C, in 50 mm sodium phosphate, pH 8, containing 10% (vol/vol) acetonitrile. Lys-C (1.0 g) digests were performed for 18 h, at 37 C, in 25 mm Tris-HCl, pH 8.5, containing 1 mm EDTA and 10% (vol/vol) acetonitrile. Glu-C (0.2 g) digests were performed for 18 h, at 25 C, in 25 mm ammonium carbonate, pH 7.8, containing 5% (vol/vol) acetonitrile. Pyroglutamate digestion was performed for 24 h, at 4 C, using 1 g enzyme, in 0.1 m sodium phosphate, pH 8, containing 10 mm EDTA, 5 mm DTT, and 5% (vol/vol) glycerol. Peptide digests were chromatographed using the narrowbore hypersil C18 reverse-phase column, as described above, with fractions manually collected into 1.5 ml polypropylene tubes containing 50 l 0.2% Tween-20.
Reduction and alkylation of extracts
Small-scale extract was Seppaked and chromatographed on Mono S (CEX), pH 5.0 and active fractions pooled and lyophilized. Half the material was resuspended in 1 m Tris, pH 8.5/6 m GuHCl, containing 100 mm DTT. This sample was incubated at 45 C for 2 h, then alkylated by addition of iodoacetamide (0.3 m) for 1 h at 22 C. The material was acidified to 2% TFA and chromatographed on C8 reverse-phase HPLC. Control material was resuspended in 0.1% TFA.
Peptide analysis
Protein sequencing was performed on reverse-phase HPLC purified peptides which were subjected to pulsed liquid phase protein sequencing on an Applied Biosystems 471A Protein Sequencer (PE-Applied Biosystems, Foster City, CA) or on a Hewlett Packard G1000A Protein Sequencer (Hewlet-Packard, Palo Alto, CA).
For amino acid analysis, the sample was hydrolyzed under vacuum, at 110 C for 24 h in 6 m HCl, containing 0.2% (vol/vol) phenol and 0.2% (vol/vol) thioglycolic acid. Quantitative analysis was performed on a Beckman 6300 amino acid analyzer.
Mass spectrometry was performed on reverse-phase HPLC purified peptides on a PE Sciex (API3ϩ) triple quadrupole mass spectrometer (PE-Sciex, Toronto, Canada) or on a Voyager-DE matrix-assisted laser desorption/ionization (MALDI)-time-of-flight (TOF) mass spectrometer (Perspective Biosystems, Framingham, MA).
Results
Characterization of pituitary extracts
For initial characterization studies, pituitaries were extracted using acid mix media (50 pituitaries/5 ml) and fractionated on a Brownlee C8 reverse-phase column. Fractions were divided into 0.5 ml aliquots, lyophilized and assayed for CT-like activity using RIA with the anti-sCT antisera 1464 or PAb, or in bioassay, measuring cAMP stimulation in HEK-293 cells stably transfected with the cloned rat C1a CT receptor. Untransfected, parental HEK-293 cells were used as a negative control.
While sCT-I was not detected using either of the anti-sCT antisera (not shown), bioactivity was observed in the cAMP accumulation assay with C1a transfected cells (Fig. 1, B and C), with the predominant activity peak occurring at approximately 31% acetonitrile. No corresponding activity was seen when material was assayed in untransfected cells, although a minor peak of activity, eluting at approximately 29% acetonitrile, was detected in both cell lines (Fig. 1, B and C) . To confirm that the activity monitored by the cAMP assay, in C1a expressing cells, was specifically generated by the CT receptor, the material was assayed in the presence and absence of the CT receptor antagonist AC512. Using 10 Ϫ6 m AC512, the dose-response curve to sCT was shifted approximately 1.5 orders of magnitude to the right (Fig. 1A) . In the presence of this concentration of antagonist, the major activity peak at 31% acetonitrile was abolished (Fig. 1B) . How-ever, the minor activity peak, detected in both transfected and untransfected cells, was not blocked by the antagonist (Fig. 1C) , indicating that stimulation of cAMP, in this case, occurs by activation of unrelated receptors. Throughout the remainder of this paper, the specific CT receptor-mediated activity will be referred to as pituitary CT.
Large-scale purification of pituitary CT
Each of the protocols used in the large-scale purification of peptides was validated in a minimum of two separate smallscale experiments. Protocols that increased the purity of the peptide and were reproducible in small-scale were considered viable for large-scale purification procedures (results not shown).
For large-scale purification of pituitary CT, 3000 pituitaries were homogenised in acid mix media, centrifuged and the supernatant filtered through Miracloth and lyophilized as described. The first two steps in the purification involved sequential batch application to and elution from a Vydac C18 (5 ϫ 1 cm) reverse-phase and a SP Sepharose HP (16 ϫ 1 cm) CEX column, respectively. Recoveries are listed in Table 1 .
Following batch elution from the CEX column, the pituitary extract was resuspended and fractionated on a Sephadex G-50 SEC column. Resuspension of the sample in the running buffer of 6 m GuHCl required a slightly greater volume (ϳ10 ml) than was optimal for the column, due to the combined high concentration of protein and GuHCl. Nonetheless, a significant purification (ϳ36-fold) was achieved ( Fig. 2; Table 1 ). Active fractions were pooled and diluted 1:1 with dH 2 0, to reduce the GuHCl concentration, and then fractionated on a preparative C8 reverse-phase column. Activity eluted in a single peak, corresponding to approximately 31.5% acetonitrile ( Fig. 3; Table 1 ). These fractions were then applied to a Hypersil C18 column using HFBA as the ion-pairing agent. Activity corresponded to the peak with a retention time of 34 min, which was well separated from the bulk of the protein (Fig. 4A) . This peak was subsequently applied to a Hypersil C18 narrowbore column. The activity co-eluted with a single, apparently homogeneous peak, with a retention time of 38.1 min (Fig. 4B ). An aliquot (40 l; ϳ1/10) of the active peak was subjected to N-terminal sequencing by Edman degradation. However, no sequence was obtained, indicating that the peptide was N-terminally blocked. The remaining material was analyzed as described below.
In an attempt to obtain peptide sequence, aliquots of the CT-like peptide were digested with the aminopeptidases trypsin, Asp-N, Glu-C, and Lys-C. Resulting digests were rechromatographed on the narrowbore Hypersil C18 column (Fig. 5) . No digestion occurred with Asp-N, whereas only partial digestion occurred with Glu-C. Novel, overlapping sequence was obtained from peptide peaks from each of the trypsin
[(K/R)S(E/Q)SP], Lys-C [KSQXP] and Glu-C
[EKSQXP] digestions. The consensus sequence for this fragment was EKSQSP. In each case, the sequence ended abruptly with the proline residue, independent of the level of peptide in the preceding cycle, consistent with termination of the sequence. Comparison of the sequence with the EMBL, GenBank, and SwissProt databases indicated no exact matches to known protein and peptide sequences. An alignment of the pituitary CT with known sequences for CT, amylin and CT gene-related peptides sequences is present in Fig. 6 . To determine whether the N-terminal blockage was caused by cyclization of an N-terminal glutamine to pyroglutamate during extraction, an aliquot of material was also digested with pyroglutamate aminopeptidase. No shift in the HPLC profile of the peptide was found (not shown), suggesting that the N-terminal residue was not pyroglutamate.
To further characterize the pituitary CT, aliquots of material were subjected to amino acid composition and mass spectrometric analyses. Although the amino acid analysis used does not detect cysteine or tryptophan residues (due to degradation) and does not discriminate between aspartic acid/asparagine (Asx) or glutamic acid/glutamine (Glx) residues, the resulting composition revealed a peptide of at least 29 amino acids (Table 2) . No methionine or histidine residues were present; however, a low level signal for tyrosine (0.45, Table 2 ) was present, and while this was called as absent in Table 2 , it is possible that one of the remaining residues is a tyrosine. The presence of two residues designated Asx, combined with the observation of lack of digestion by Asp-N, indicated that 2 asparagines were present. A search of the amino acid composition against the SwissProt protein database (http://expasy.hcuge.ch/ch2d/aacompi.html) did not identify any known protein. Electrospray mass spectrometric analysis indicated two molecular weight components: a major component of 3267 Da and a minor component of 3540 Da; however, time-of-flight analysis revealed only a single mass of 3264 Da, suggesting that the minor peak in the electospray analysis may have been a contaminant. Based on the protein concentration determined from the amino acid analysis and the mass of 3267 Da, approximately 1434 ng of peptide was calculated to be present following the initial narrowbore C18 separation. This is three times greater than the level of peptide calculated from the cAMP bioassay, assuming a specific activity equivalent to that of sCT (Table 1) .
Although the procedure for amino acid analysis used in the current paper does not detect cysteine residues, reduction and alkylation of partially purified pituitary CT resulted in a decreased retention time of bioactive material, following C8 reverse-phase HPLC (not shown). This is consistent with the presence of cysteines in the sequence, which is an invariant feature of all known CT peptides.
Large-scale purification of sCT-like peptide from rat brain diencephalon
We have previously shown that the rat brain diencephalon contains sCT-I (9) . In this study, we have carried out largescale purification of extracts from 4000 diencephalons. Preliminary analysis of material separated by C8 reverse-phase HPLC, using RIA with either the 1464 or PAb antibodies, indicated that the primary recognition products of the two antibodies differed (not shown). Consequently, fractionated material was assayed for sCT-I using both antibodies.
As with pituitary extracts, extractions were carried out in acid mix media and initial purification used batch application to and elution from the Vydac C18 reverse-phase and SP Sepharose CEX columns. Recoveries for each step in the purification are listed in Table 3 .
The brain extract was first applied to the preparative C8 reverse-phase HPLC column, where gradient elution resulted in a broad peak of activity in both RIAs (not shown). Active fractions from the C8 reverse-phase analysis were resuspended in 4.5 ml of 6 m GuHCl and fractionated on the Sephadex G-50 column. The majority of the protein eluted as one major peak (Fig. 7) . Interestingly, the RIA profiles reveal three distinct peaks, with the level of activity in each peak differing markedly depending upon the anti-sCT sera used. The immunoreactivity in the first peak (SEC I) eluted in the void volume of the column (mol wt Ͼ 13,700), whereas the immunoreactivity in the second peak (SEC II) eluted just after ribonuclease A (mol wt 13,700), and the immunoreactivity in the third peak (SEC III) eluted just before aprotinin (mol wt 6,500). The 1464 antiserum principally detected the two peaks of higher molecular weight (Fig. 7A) . The PAb antiserum detected these two peaks and also the lower molecular weight species, SEC III (Fig. 7B) .
Aliquots of the SEC peaks were assayed for bioactivity with the cAMP stimulation assay using rat C1a and C1b receptor-transfected HEK-293 cells (Fig. 8) . In C1a receptorexpressing cells, SEC I had no significant activity (Fig. 8A) , whereas undiluted SEC II appeared to give a small stimulation (Fig. 8B) . No stimulation was observed in the untransfected cells. However, SEC III stimulated significant cAMP production in C1a receptor-expressing cells, in a dosedependent manner (Fig. 8C) . Comparison of the activity levels in the cAMP assay and the RIA, with sCT as standard, indicated approximately three times greater activity in the bioassay (Table 3) . A small response was also observed in the untransfected cell line. This was most likely due to activity of non-CT peptides, as the extract was still crude at this stage. In the C1b receptor-expressing cells, which exhibit a high basal level of cAMP, the cAMP levels were unaffected. Because the SEC III fraction was biologically active and exhibited greatest separation from contaminating protein, this material was used for subsequent purification, with activity monitored by RIA with the PAb antiserum.
Sequential reverse-phase chromatography allowed purification of active material to near homogeneity, following C8 narrowbore chromatography (Table 3 , Fig. 9 ). However, recoveries were relatively poor, and no sCT-I activity was detected after application of postnarrowbore material to a microbore SGE column (250 ϫ 1 mm) ( Table 3) .
Discussion
The existence of sCT-like peptides in the CNS of a number of species has been previously noted, where it is proposed to play a role as a neurotransmitter or neuromodulator (8 -11,  15, 16, 28 -30) . Due to the lack of the thyroid-derived form of Fractions were collected manually. The protein profile was measured at 280 nm. An aliquot of each fraction (1/100 dilution) was lyophilized and assayed. The black bar indicates the peak containing activity. B, Fractionation by narrowbore HPLC. Lyophilized pituitary extract was resuspended in 1 ml dH 2 0, microfuged for 5 min, and loaded onto a Hypersil C18 reverse-phase column (10 ϫ 2.1 mm) at a flow rate of 250 l/min. Elution was achieved with a linear gradient of 4 -80% acetonitrile/0.1% TFA at a flow rate of 100 l/min. Protein peaks, measured at 214 nm, were collected manually into 1.5-ml tubes containing 50 l 0.2% Tween-20. An aliquot (1/50 dilution) was lyophilized and assayed. The black bar indicates the peak containing activity.
CT in the CNS, we proposed that an sCT-like peptide may be the endogenous ligand for the central CT receptors (9) . In this paper, we describe the purification and partial characterization of CT-like peptides from brain and pituitary. The pituitary peptide was more amenable to purification and, based upon its molecular weight, amino acid composition and unique partial sequence, proved to be a novel peptide. For brain material, a protocol for near homogeneous purification of the activity is described. Both brain and pituitary peptides were biologically active at the cloned rat C1a CT receptor; however, only the brain-derived material exhibited cross-reactivity with C-terminally directed anti-sCT antisera.
Lack of recognition of the pituitary peptide by the anti-sCT antisera was surprising, in particular, because the PAb antibody reveals, immunohistochemically, sCT-I in the mouse pituitary carcinoma cell line ␣-TSH (16). The basis for this discrepancy is unclear but may be related to different reactivities in immunohistochemistry vs. RIA. Nonetheless, other anti-sCT sera have detected sCT-I release from anterior pituitary cells (15) . Immunohistochemical staining of rat pituitaries with anti-hCT and anti-rCT sera has also been reported, although the pituitary CT cross-reacted with only 2 of 15 anti-hCT/rCT sera (4) . Together, the data indicate that, whereas the pituitary CT shares structural epitopes with CT peptides, it is not identical to either sCT or rCT. This was confirmed by the amino acid composition analysis in Table  2 and by the unique molecular weight of 3267 Da. Recently, Shah et al. (31) reported that the anti-sCT serum used in their studies may recognize the N-terminal region of the sCT molecule containing the disulfide-bridged loop. This suggests that the pituitary CT and sCT may have similar N-terminal residues. As the N-terminus is highly conserved, it may also explain the cross-reactivity of the limited number of antirat/ human CT antisera in the early immunohistochemical studies (4) . If the principal site of sequence convergence between pituitary CT and sCT-like peptides is in the N-terminus, this would explain the lack of cross-reactivity with the 1464 and Peninsula anti-sCT sera, which are C-terminally directed.
Conservation of sequence in the N-terminus is not surprising as this region of CT is both highly conserved across species and is crucial for the agonist activity of CT peptides (32) . Structure-activity studies demonstrate that residues 3-6 of sCT are particularly important for its biological activity (32) . In the current study, the pituitary CT activated adenyl- (27) . c Activity calculated from cAMP stimulation assay with sCT used as standard.
ate cyclase in cell lines with heterologously expressed CT receptors. The specificity of the response was demonstrated by 1) the stimulation of cAMP production in CT receptorcontaining cells but not in the CT receptor-negative cells, and 2) abolition of activity by the CT receptor antagonist, AC512. Thus, conservation within the N-terminal region of the peptide is likely. In contrast, considerable divergence in the mid to C-terminus of the peptides can be tolerated without major effect on peptide activity. Most of the amphiphilic core of sCT can be replaced with other residues of similar hydrophobicity without markedly impairing either the biological activity or the ability to bind CT receptors (33) . Similarly, AC413, a chimeric analog of sCT (8 -32) and amylin, which is approximately 50% substituted by amylin residues, maintains high affinity for CT receptors (34) . Therefore, the lack of crossreactivity with the C-terminally directed anti-sCT anti-sera used in this study is not necessarily surprising. Using conventional chromatography, an approximately 900-fold purification of the pituitary CT was achieved. Activity analyzed on the narrowbore reverse-phase HPLC column eluted as a homogenous peak, with a principal mass of 3267 Da. This differs from the molecular mass of both rat CT (3400 Da) and sCT (3432 Da). Based on the assumption that the purified peptide remained fully active, the pituitary CT is approximately 3-fold less potent than sCT. However, minor structural modifications during extraction and purification, which affect biological activity, cannot be ruled out.
The procedure used for the current amino acid analysis was unable to resolve all the component residues. However, based on the existing composition, the 3267-Da mass predicts a 32-amino acid peptide. As cysteine residues are degraded by this procedure, it is likely that the remaining residues include cysteines. Reduction and alkylation of the pituitary CT altered its retention time in reverse-phase HPLC, suggesting that disulfide-bridged cysteines are indeed present. This is consistent with the conservation of the cysteinebridged N-terminal loop that occurs in all known CT peptides. The abrupt termination of sequence at proline, for each of the protease digestion peaks yielding sequence, implies that this sequence may represent the C-terminal end of the peptide. This would be consistent with the invariant proline at the end (position 32) of all known CTs. In CT, the proline is amidated and is also essential for biological activity (35) .
The exact physiological role of endogenous pituitary CT is not resolved. Nonetheless, CT receptors are present in both intermediate pituitary (14) and anterior pituitary (15, 16, 31) . Furthermore, release of endogenous CT-like peptides from cultured anterior pituitary cells has been demonstrated (15) , and inhibition of PRL release occurs in response to both exogenous and endogenous CTs (15, 31) . More recently, Shah and colleagues (31) demonstrated a marked in vivo increase in PRL secretion following injection of specific anti-sCT antisera. This antisera did not cross-react significantly with rat CT, suggesting that the action was mediated by binding to and inhibiting nonthyroidal CTs. Together, as proposed by Shah and colleagues, this data suggests that CT may be a physiological regulator of PRL secretion and that, in this action, endogenous pituitary CT may be acting in a paracrine or autocrine fashion.
Although purification to homogeneity was not achieved for the sCT-like peptide from diencephalon, a number of important observations were made. Diencephalon extract fractionated on a Sephadex G-50 column revealed multiple immunoreactive peaks. The 1464 antisera detected primarily the higher molecular weight peaks (SEC I and SEC II), whereas the PAb anti-sera detected both of the two peaks seen with the 1464 antisera, as well as a third form (SEC III), which had the highest biological activity. Multiple immunoreactive forms of CT also occur in tissue and blood samples, where 2-7 peaks are observed (36 -40) . While the number of peaks seen in these studies is dependent on antisera specificity, both antisera used in the current study are Cterminally directed and demonstrate similar general specificity for peptide recognition. The difference between the anti-sCT sera used in this study may relate to the sCT peptide used to raise the antisera as the 1464 was raised against an R 11, 18 K 14 modified sCT (23) conjugated to BSA, rather than native sCT. The identities of the higher molecular mass forms are unclear, although it is probable that they derive from precursor forms of the peptide (thyroid-derived procalcitonin is approximately 11,000 Da), or polymers of CT resulting from intermolecular disulfide bridge formation and/or high molecular weight complexes formed by disulfide bridge linkage of the monomer to an unrelated protein (36, 37) . It is possible that SEC I and SEC II represent such high molecular mass forms of CT. Consistent with previous studies, the high molecular mass forms of SEC I and SEC II were essentially biologically inactive (36, 37) .
Although the brain and pituitary CT-like peptides appear to be different, both are likely released from precursor forms. It is not surprising that high molecular mass forms of CT were not detected in the pituitary as they tend to be biologically inactive. However, bands of molecular mass of approximately 23 and 6.5 Da, along with a band equivalent to monomeric CT of 3.5 Da, were immunoprecipated with antisCT and anti-hCT sera from anterior pituitary cell lysates (15) . This data suggest that precursor forms of the CT-like peptide also occur in pituitary. Whether or not both peptides derive from a common precursor remains to be resolved and relies on either full sequencing of the brain and pituitary peptides or isolation of their cDNAs.
In summary, conventional chromatography was used to partially purify CT-like peptides from both rat brain and pituitary, during which different assay systems were used to monitor their activity. Although the pituitary CT shares features of commonality with characterized CT peptides, determination of the amino acid composition and molecular weight indicated the purification of a novel peptide which may function as an endogenous regulator of pituitary function.
